News

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
The once-monthly drug is still under study but could provide added convenience and another option for patients.
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...